New research to deliver cancer-killing viruses to tumour cells
Oxford scientists announce laboratory success using a new linker technique to bond cell-killing agents to cancer-targeting antibodies
Scientists at the University of Oxford have invented a new linker to attach a cancer-killing virus to a tumour-targeting antibody, in research published in the scientific journal Molecular Immunology.
The new linker is built of molecular human components and is designed to bond a cell-killing virus to an antibody directed against a target cell, such as cancerous cell. Against Breast Cancer, who funded some of the research, hope that this method could be used to destroy secondary breast cancer cells that have trafficked from the breast to other parts of the body, namely the bone, liver, lung or brain.
Iona Easthope who performed some of the research says: “We were excited to see that this linker connected a virus to the breast-cancer cell-targeting antibody in a stable manner at 37 degrees, as well as successfully re-targeting the viruses to enter breast cancer cells without affecting the healthy cells.”
The re-targeting adaptor linker is an improvement on a similar product made up of bacterial components, which were recognized by the body as a threat and broken down before the treatment could be allowed to reach target cells and take effect.
Dr Max Crispin was the one of the lead investigators on the project. “Humanized bispecific adaptors offer the promise of a versatile retargeting technology that can exploit both clinically approved and new experimental therapeutic antibodies for cancer and other diseases. We have dedicated this research article to Dr Chris Scanlan who started this project and sadly passed away after a short battle with cancer.”
One in five breast cancer cases result in fatal metastases, when breast cancer cells break away from the original tumour site and establish new tumours in bone, lung, liver or brain. The new linker could pave the way for better, more targeted treatment methods for many types of cancer, including Stage IV secondary cancers that have spread throughout the body.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance